KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Capital Expenditures (2016 - 2024)

Historic Capital Expenditures for Arbutus Biopharma (ABUS) over the last 16 years, with Q4 2024 value amounting to $86000.0.

  • Arbutus Biopharma's Capital Expenditures changed N/A to $86000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $86000.0, marking a year-over-year decrease of 1041.67%. This contributed to the annual value of $182000.0 for FY2024, which is 8194.44% down from last year.
  • As of Q4 2024, Arbutus Biopharma's Capital Expenditures stood at $86000.0.
  • In the past 5 years, Arbutus Biopharma's Capital Expenditures registered a high of $859000.0 during Q2 2023, and its lowest value of $1000.0 during Q2 2024.
  • In the last 5 years, Arbutus Biopharma's Capital Expenditures had a median value of $91000.0 in 2022 and averaged $161176.5.
  • As far as peak fluctuations go, Arbutus Biopharma's Capital Expenditures surged by 85757.58% in 2021, and later plummeted by 9988.36% in 2024.
  • Arbutus Biopharma's Capital Expenditures (Quarter) stood at $152000.0 in 2020, then crashed by 61.84% to $58000.0 in 2021, then surged by 131.03% to $134000.0 in 2022, then crashed by 76.12% to $32000.0 in 2023, then soared by 168.75% to $86000.0 in 2024.
  • Its last three reported values are $86000.0 in Q4 2024, $1000.0 for Q2 2024, and $95000.0 during Q1 2024.